<p>Bengaluru-based pharmaceutical company Biocon Limited, in a statement on its Q42021 performance, stated that the company will not be giving any dividend to its shareholders.</p>.<p>In the statement, the pharma major said, “On account of the uncertainty created by an unprecedented second wave of the Covid-19 pandemic and the continued investments in R&D and Capex, the Board of Directors has decided it would not be appropriate to declare a dividend for FY21.”</p>.<p>Biocon Limited posted a 4% decline in net profits from Rs 789 crore in FY20 to Rs 754 crore in FY21. However, the company’s consolidated revenue grew 14% from Rs 6,462 crore in FY20 to Rs 7,360 crore in FY21.</p>.<p>A major in the biologics space, the company has grown 21% from Rs 2,315 crore in FY20 to Rs 2,800 crore in FY21. While there has been significant growth in the biologics space year-on-year, comparing revenues in Q4 with Q3, there is a decline in Q4. While the company made Rs 769 crore in Q3 FY21 from biosimilars, it made Rs 664 crore in Q4 FY21.</p>.<p>However, as compared to Q4 of FY20, the company marked an increase of 53% in the biosimilar space from Rs 433 crore to Rs 664 crore in Q4 FY21. On the other hand, its generic business has grown 6% over the last year and the research segment 9%.</p>
<p>Bengaluru-based pharmaceutical company Biocon Limited, in a statement on its Q42021 performance, stated that the company will not be giving any dividend to its shareholders.</p>.<p>In the statement, the pharma major said, “On account of the uncertainty created by an unprecedented second wave of the Covid-19 pandemic and the continued investments in R&D and Capex, the Board of Directors has decided it would not be appropriate to declare a dividend for FY21.”</p>.<p>Biocon Limited posted a 4% decline in net profits from Rs 789 crore in FY20 to Rs 754 crore in FY21. However, the company’s consolidated revenue grew 14% from Rs 6,462 crore in FY20 to Rs 7,360 crore in FY21.</p>.<p>A major in the biologics space, the company has grown 21% from Rs 2,315 crore in FY20 to Rs 2,800 crore in FY21. While there has been significant growth in the biologics space year-on-year, comparing revenues in Q4 with Q3, there is a decline in Q4. While the company made Rs 769 crore in Q3 FY21 from biosimilars, it made Rs 664 crore in Q4 FY21.</p>.<p>However, as compared to Q4 of FY20, the company marked an increase of 53% in the biosimilar space from Rs 433 crore to Rs 664 crore in Q4 FY21. On the other hand, its generic business has grown 6% over the last year and the research segment 9%.</p>
